The startup develops pharmaceutical drugs targeting autoimmune diseases by utilizing a unique mechanism that enhances skin health from within the body. This approach aims to improve treatment outcomes for patients suffering from skin-related autoimmune conditions.

CynosBio is a specialty pharma that develops autologous regenerative medicine products, using a patient’s own cells cultured on human amniotic membrane or collagen matrices. Its marketed eye treatment, Sakurashi®, restores corneal surface health from oral mucosal epithelial sheets, while its IK‑01 therapy aims to regenerate knee cartilage by implanting cultured autologous chondrocytes. Both products are fully developed, manufactured, and distributed in‑house, enabling streamlined production and regulatory control.

Eli provides a mobile application and web platform that engages employees in corporate social responsibility (CSR) initiatives through gamified challenges and collaborative idea-sharing. This approach enhances internal communication, fosters a culture aligned with sustainability values, and enables companies to track engagement metrics and environmental impact effectively.

The startup develops pharmaceutical compounds targeting orphan and intractable diseases, specifically in psychiatry, neurology, and pulmonary arterial hypertension. By providing cost-effective treatment options, the company enables physicians to manage rare and incurable conditions more effectively.

The startup develops fully human and canine-feline therapeutic monoclonal antibodies for human and animal health applications. By providing these licensed antibodies to pharmaceutical companies, it enhances drug development opportunities in the biopharmaceutical sector.

Om provides access to massive, internally generated datasets detailing proteome-wide small molecule binding data. Researchers can programmatically query billions of protein and small molecule interaction data points to identify therapeutic opportunities instantly. The platform leverages synthetic biology and pico-scale engineering to accelerate the transition from hypothesis to launching a discovery program.

The startup develops lipid nanoparticles (LNPs) that specifically target myeloid cells, enabling the direct delivery of therapeutic agents to macrophages and dendritic cells. This technology facilitates the development of treatments for cancer, autoimmune diseases, fibrosis, and infectious diseases by enhancing the precision of drug delivery.

URUS Beast utilizes blockchain technology to provide secure ownership and management of healthcare data, enabling users to control access while ensuring confidentiality. The NFTrace system offers real-time tracking of medical assets, while smart contracts and the cPERK rewards system enhance trust and engagement within the healthcare community.

This company develops next-generation radiopharmaceuticals utilizing the copper radioisotope 64Cu for cancer diagnosis and therapy. Their focus is on creating domestic radiopharmaceuticals that enable "visible" cancer treatment for intractable cancers. This work aims to connect advanced science with medicine to contribute to patient health and well-being.